N30 Pharma Finds $30M More
Boulder-based N30 Pharma has raised $30M more in a mezzanine funding round, the company disclosed last week, which came from Wellington Management, RA Capital Management, Jennison Associates, Rock Springs Capital Management, and Sabby Management, along Deerfield Management and others. The company--which is developing treatments for cystic fibrosis--said the funding goes towards advancing its lead compound, N91115. The company has now raised north of $115M in funding.
posted on Tuesday, November 25, 2014 (Link to more information)
Related companies:
N30 Pharma
Related stories:
> N30 Pharma In Deal With NitroMed
> N30 Expands Board
> N30 Pharma Raises $30M
> N30 Pharma Gets Funding
> Nivalis Sets IPO Range
Techrockies.com Home